Expertos Invitados





ANALIZAN LAS CARACTERISTICAS DE LOS EFECTOS ADVERSOS DE LOS ANTIRRETROVIRALES EN LA INFECCION POR VIH

(especial para SIIC © Derechos reservados)
Si bien la terapia antirretroviral de gran actividad ha disminuido notablemente la morbimortalidad relacionada con el VIH, el tratamiento prolongado puede ser complicado debido a los problemas que generan la adhesión y los efectos adversos.
Autor:
Erika Santos corraliza
Columnista Experto de SIIC

Institución:
Hospital Universitario

Artículos publicados por Erika Santos corraliza
Coautor
Aurelio Fuertes Martín* 
Hospital Universitario, Salamanca, España*
Recepción del artículo
14 de Mayo, 2008 		Aprobación
15 de Julio, 2008
Primera edición
27 de Marzo, 2009 		Segunda edición, ampliada y corregida
7 de Junio, 2021

ANALIZAN LAS CARACTERISTICAS DE LOS EFECTOS ADVERSOS DE LOS ANTIRRETROVIRALES EN LA INFECCION POR VIH

Resumen
La utilización de la terapia antirretroviral combinada ha mejorado el pronóstico de la infección por VIH. Estos regímenes terapéuticos han disminuido de forma significativa la morbimortalidad relacionada con el VIH en los países desarrollados. Sin embargo, el tratamiento prolongado con estas combinaciones de fármacos puede ser complicado debido a los problemas que generan la adhesión y los efectos adversos. Todos los antirretrovirales pueden producir efectos secundarios a corto y largo plazo. El riesgo de efectos adversos específicos varía según el fármaco, la clase a la que pertenece e incluso la susceptibilidad individual. El mejor conocimiento de los efectos adversos de los fármacos antirretrovirales es necesario para intentar optimizar el tratamiento en pacientes infectados por el VIH.

Palabras clave
VIH, tratamiento antirretroviral, efectos adversos, toxicidad mitocondrial, lipodistrofia


Artículo completo
(castellano)
Extensión:  +/-9.34 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Side Effects of Antiretroviral Therapy. Fisiopathology, Clinical Manifestations and Treatment

Abstract
The use of combination antiretroviral therapy has improved the prognosis of HIV infection. These regimens have significantly decreased HIV-related morbidity and mortality in developed countries. However, prolonged treatment with combination regimens can be difficult because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies according to specific drugs, drug class and even, individual susceptibility. A better understanding of the adverse effects of antiretroviral agents is of interest to try to optimize therapy in HIV infected patients.

Key words
HIV, antiretroviral therapy, side effects, mitochondrial toxicity, lipodistrophy

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Infectología
Relacionadas: Atención Primaria, Bioquímica, Diagnóstico por Laboratorio, Farmacología, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 9.34 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Erika Santos Corraliza, Hospital Universitario Servicio de Medicina Interna II, 37007, Paseo de San Vicente, 58-182, Salamanca, España
Bibliografía del artículo

1. Palella FJ Jr, Chmiel JS, Moorman AC, Holmberg SD, and the HIV outpatient study investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 16:1617-26, 2002.
2. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin, JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 16:1663-71, 2002.
3. Lozano F, Viciana P. Efectos adversos del tratamiento antirretrovírico: importancia y espectro clínico. En: Lozano F, Viciana P, editores. Efectos adversos del tratamiento antirretrovírico. Madrid: Scientific Communication Management, SL, pp.11-18, 2003.
4. www.hiv-farmacogenomics.org.
5. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet 356:1423-30, 2000.
6. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet 358:1322-7, 2001.
7. Reisler RB, Han C, Burman WJ, Tedaldi EM and Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 34:379-386, 2003.
8. Le Moing V, Chene G, Leport C, Lewden C, Duran S, Garré M et al. Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human inmunodeficiency virus-infected patients. Clin Infect Dis 34:239-47, 2002.
9. Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MCJM, Stricker B, Mulder WMC et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 16(5):737-45, 2002.
10. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Cozzi Lepri A, et al. Reasons for modification and discontinuation of antiretrovirals: results for a single treatment centre. AIDS 15:185-94, 2001.
11. SMART study group. CD4+ Count-Guided Interruption of Antiretroviral Treatment. N Engl J Med 355:2283-96, 2006.
12. Moltó J, Rudi N, Bonafont X, Clotet B. Monitorización terapéutica de los niveles plasmáticos de los fármacos antirretrovirales. Situación actual. Enf Emerg 3:170-5, 2003.
13. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356:1723-35, 2007.
14. DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. Lancet 371:1417-26, 2008.
15. Mu H, Chai H, Lin PH, Yao Q, Chen C. Current Update HIV-associated vacular disease and endothelial dysfunction. World J Surg 31:632-43, 2007.
16. Domingo, P. Toxicidad mitocondrial. En: Lozano F, Viciana P, editores. Efectos adversos del tratamiento antirretrovírico. Madrid: Scientific Communication Management, SL, pp. 19-45, 2003.
17. Falcó V, Rodríguez D, Ribera E, Martinez E, Miró JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human inmunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 34:838-46, 2002.
18. Pulido F. Hiperlactatemia. En: Polo R. Coordinadora. Actualización en el tratamiento de la lipodistrofia y alteraciones metabólicas. Madrid: GlaxoSmithKline pp. 116-21, 2003.
19. Carr A. Lactic acidemia in infection with human inmunodeficiency virus. Clin Infect Dis 36(Suppl.2):S96-100, 2003.
20. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human inmunodeficiency virus-infected patients: a review. Am J Med 107:78-84, 1999.
21. Peters BS, Winer J, Landom DN. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Am J Med 86:5-15, 1993.
22. Brown RH, Mendell JR. Distrofias musculares y otras enfermedades musculares. En: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison, Principios de Medicina Interna. 16ª ed. Madrid. McGraw-Hill Interamericana pp. 2783-97, 2005.
23. Lewis W, Dalakas M. Mitochondrial toxicity of antiviral drugs. Nat Med 1:417- 22, 1995.
24. Lutton JD, Mathew A, Levere RD, Abraham NG. Role of heme metabolism in AZT-induced bone marrow toxicity. Am J Hematol 35:1-5, 1990.
25. Brew B, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV distal symmetrical sensory polyneuropathy. Program and abstracts of the 8th Conference on Retroviruses and Opportunistics Infections Chicago, Illinois, Abstract 9, 2001.
26. Fallon J, Ait-Khaled M, Thomas DA, Brosgart CL, Eron Jr JJ, Feinberg J, et al. HIV-1 genotype and phenotype correlate with virológical response to abacavir, amprenavir and efavirenz in treatment experienced patients. AIDS 16:387-96, 2002.
27. Rivero A, Delgado R. Reacciones de hipersensibilidad. En : En: Lozano F, Viciana P, editores. Efectos adversos del tratamiento antirretrovírico. Madrid: Scientific Communication Management, SL, pp. 63-87, 2003.
28. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23:1603-14, 2001.
29. Mallal S, Philips E, Carosi C, Molina JM, Workman C, Tomazic J, et al. HLA-B 5701 screening for hypersensitivity to abacavir. N Engl J Med 358:637-9, 2008.
30. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B 5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 21:2533-4, 2007.
31. Encinas de la Iglesia J, Pérez García ML, Fuertes Martín A. Efectos secundarios del tratamiento antirretroviral. FMC 9(5):343-9, 2002.
32. Alonso Claudio G, Fuertes Martin A, De Dios Perrino S, Arévalo Velasco A. DRESS syndrome associated with nevirapine theraphy. Arch Intern Med 161:2501-2, 2001.
33. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 351:252-5, 1998.
34. Vitezica ZG, Milpied B, Lonjou C, Borot N, Ledger TN, Lefebvre A, et al. HLA-DRB101 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 22:540-1, 2008.
35. Núñez M, Soriano V. Hepatotoxicidad del tratamiento antirretroviral. En: F. Lozano, P. Viciana, editores. Efectos adversos del tratamiento antirretrovírico. 1 ed. Madrid, Roche Farma, pp. 47-62, 2003.
36. Updated Adult Guidelines. http://aidsinfo.nih.gov/guidelines, October 6, 2005.
37. ClarK S, Creighton S, Portmann B, Taylor C, Wendon J, Cramp M. Acute liver failure associated with antirretroviral treatment for VIH: a report of six cases. J Hepatol 36:295-301, 2002.
38. Arribas JR, Gonzalez J. Manejo de los efectos secundarios frecuentes del tratamiento antirretroviral en adultos. En : González J, Moreno S, Rubio R, editores. Infección por VIH 2000. Madrid:, Doyma, pp. 241-75, 2001.
39. Corzo JE, Gómez JM. Otros efectos adversos del tratamiento antirretrovírico. En : Lozano F, Viciana P, editores. Efectos adversos del tratamiento antirretrovírico. Madrid: Scientific Communication Management, SL, pp. 247-54, 2003.
40. Staszewski S, Morales-Ramírez J, Tashima KT. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment oh HIV-1 infection in adults. Study 006 Team. N Engl J Med 341:1865-73, 1999.
41. Levin J. DUET-1 and DUET-2: TMC125 versus placebo in treatment-experienced HIV-1-infected patients. 4th IAS (Intl AIDS Society) Conference on HIV pathogenesis, treatment and prevention. Sidney, Australia, 22-25 Julio 2007.
42. Roca B. Transtornos metabólicos relacionados con el VIH y el tratamiento antirretroviral. An Med Interna 20(11):585-93, 2003.
43. Cheseaux JJ, Jotterand V, Aebi C, Gnehm H, Kind C, Nadal D, et al. Hy- perlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr 30:288-93, 2002.
44. San Martín M. HIV and HAART: cardiovascular repercusión. Nutrition and Metabolic Disorders in HIV Infection 1:5-13, 2002.
45. Petit JM, Duong M, Florentin E, Duvillard L, Lizard G, Gambert M, et al. Down expresión of LDL receptor in HIV-infected patients on HAART: Quantification by flow cytometry. Program and abstract of the 8th Conference on Retroviruses and Opportunistics Infections, Chicago, Illinois, Abstract 661, 2001.
46. Riddle TM, Kuhel DG, Woolwtt LA, Fichtenbaum C, Hui DY. HIV protease inhibitor therapy increases hepatic lipoprotein production via stabilization of activated sterol regulatory element-binding protein-1 (SREBP-1) in the nucleus. Program and abstracts of the 8th Conference on Retroviruses and Opportunistics Infections, Chicago, Illinois, Abstract 659, 2001.
47. Smart EJ, Mateev S, Kincer J, Greenberg R,N. Protease inhibitors upregulate SR-BI and HDL-dependent colesterol uptake in human macrophages: amechanism that may enhance foam cell formation. Program and abstracts of the 8th Conference on Retroviruses and Opportunistics Infections, Chicago, Illinois, Abstract 662, 2001.
48. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human inmunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32:130-9, 2001.
49. Martinez E, García MA, Conget I, Buira E, Blanco JL, Mallolas J, et al. Incidence, characteristics, and prognosis of diabetes mellitus associated with protease inhibitors. 7th Conference on Retroviruses and Opportunistics Infections, San Francisco, Abstract 16, 2000.
50. Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterolregulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 16:1587-94, 2002.
51. Miralles C. Insuline resístanse in HIV patients: pathogenic role of dyslipidaemia and body fat redistribution. En: Nutrition and Metabolic Disorders in HIV infection 2:79-97, 2003.
52. O'Moore-Sullivan TM, Prins JB. Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med J Aust 176:381-6, 2002.
53. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15:1389-98, 2001.
54. Koutkia P and Grinspoon S. HIV-associated lipodystrophy: patogénesis, prognosis, treatment and controversies. Annu Rev Med 55:303-17, 2004.
55. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, Kotler DP. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Synd 30:379-91, 2002.
56. Koppel K, Bratt G, Eriksson M, Sandstrom E. Serum lipid levels associated wiyh increased risk for cardiovascular disease is associated with highly active antirretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS 11(7):451-55, 2000.
57. Bernasconi E, Uhr M, Telenti M, Bernasconi A, Magenta L, Moccetti T. Homocysteinemia in HIV-1 infected patients treated with HAART. Program and abstracts of the Seventh European Conference on Clinical Aspectects and Treatment of HIV-Infection, Lisbon, Portugal, Abstract 806, 1999.
58. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, et al. Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors. AIDS 14:123-8, 2000.
59. Doung M, Cottin Y, Piroth L, Fargeot A, Lhuiller I, Bobillier M et al. Exercise stress testing detection of silent myocardial ischemia in human inmunodeficiency virus-infected patients receiving antirretroviral therapy. Clinical Infectious Diseases 34:523-8, 2002.
60. Moreno Cuerda VJ, Rubio García R, Morales Conejo M. Nuevas perspectivas en terapéuticas en el paciente con infección por el virus de la inmunodeficiencia humana politratado y en fracaso virológico. Med Clin 130:66-70, 2008.
61. Tipranavir: drug information. UpToDate, 2008.
62. Aptivus®. US Food and drug administration. 2006. Disponible en: fda.gov/medwatch/safety/2006/Aug_PIs/Aptivus_PI.pdf .
63. Darunavir: drug information. UpToDate. 2008.
64. Prezista™. US Food and drug administration. 2008. Disponible en: fda.gov/cder/foi/label/2008/021976s003s004lbl.pdf.
65. Miller KD, Masur H, Jones EC, Joe GO, Rick ME, Kelly GG et al. High prevalence of osteonecrosis of the femoral head in HIV-infectede adults. Ann Intern Med 137:17-25, 2002.
66. Blacksin MF, Kloser PC, Simon J. Avascular necrosis of bone in human inmunodeficiency virus infected patients. Clin Imaging 23:314-8, 1999.
67. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV infected patients receiving potent antiretroviral therapy. AIDS 14 (4):F63-7, 2000.
68. Clotet B, Raffi F, Cooper D, Delfraissy JF, Lazzarin A, Moyle G, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 18:1137-46, 2004.
69. Raltegravir: drug information. UpToDate. 2008.
70. FDA News. US Food and Drug administration. 2007. Disponible en: fda.gov/bbs/topics/NEWS/2007/NEW01726.html.
71. Maraviroc: patient drug information. UpToDate. 2008.
72. FDA News. US Food and drug administration. 2007. Disponible en: fda.gov/bbs/topics/NEWS/2007/NEW01677.html.
73. Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 132:306-11, 2000.
74. Tebas P. On antiretroviral guidelines and evidence based medicine. Enferm Infecc Microbiol Clin 20:241-3, 2002.
75. Rubio R, Berenguer J, Miró JM, Antela A, Iribarren JA, González J, et al. Recomendaciones de GESIDA/Plan Nacional sobre SIDA respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodefieciencia humana en el año 2002. Enferm Infecc Microbiol Clin 20:244-303, 2002.
76. Max B, Sherer R. Management of de adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis (Suppl.2):S96-116, 2000.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008